Compare TRST & ABSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TRST | ABSI |
|---|---|---|
| Founded | 1902 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 858.9M | 997.8M |
| IPO Year | 1994 | 2021 |
| Metric | TRST | ABSI |
|---|---|---|
| Price | $57.41 | $7.56 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $6.96 |
| AVG Volume (30 Days) | 92.8K | ★ 4.4M |
| Earning Date | 04-21-2026 | 05-07-2026 |
| Dividend Yield | ★ 3.25% | N/A |
| EPS Growth | ★ 26.46 | 10.64 |
| EPS | ★ 0.91 | N/A |
| Revenue | N/A | ★ $4,534,000.00 |
| Revenue This Year | N/A | $215.96 |
| Revenue Next Year | N/A | $319.10 |
| P/E Ratio | $63.02 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $32.66 | $2.24 |
| 52 Week High | $57.87 | $12.06 |
| Indicator | TRST | ABSI |
|---|---|---|
| Relative Strength Index (RSI) | 69.66 | 39.24 |
| Support Level | $51.18 | $2.56 |
| Resistance Level | N/A | $12.06 |
| Average True Range (ATR) | 1.59 | 0.72 |
| MACD | 0.15 | -0.44 |
| Stochastic Oscillator | 92.98 | 3.79 |
Trustco Bank Corp N Y is a savings and loan holding company. The core part of a business consists of accepting deposits and making loans and investments. It offers a range of both personal and business banking services. The company's product includes savings accounts; retirement accounts; money market account; mortgages; building loans; auto loans and others. The company derives revenue from the business of Banking. TrustCo lends in the geographic territory of its branch locations in New York, Florida, Massachusetts, New Jersey, and Vermont.
Absci Corp is the Artificial intelligence powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics. It enables the creation of novel biologics by unifying biologic drug discovery and cell line development into one simultaneous process. Its lead product candidate, ABS-201, is an anti-prolactin receptor (PRLR) antibody engineered with an extended half-life to support a patient-friendly dosing interval.